“Some mice were followed out to Day 209. The publication reported no overt toxicity, but normal B cells were decreased (i.e., B cell aplasia).”
✓ VerifiedFDA pharmacology/toxicology review, p. 16Source ↗
Pivotal GLP studies
No toxicology studies; published surrogate CAR-T study in lymphodepleted syngeneic tumor-bearing mice (Kochenderfer 2010)
“No toxicology studies with KTE-C19 were conducted.”
✓ VerifiedFDA pharmacology/toxicology review, p. 16Source ↗
Route in tox
Intravenous (after total body irradiation lymphodepletion in mice)
“Following intravenous injection of murine T cells expressing the anti-murine CD19 CAR into the mice, tumors were eliminated (i.e., lymphoma cells were undetectable) and animal survival was extended.”
✓ VerifiedFDA pharmacology/toxicology review, p. 3Source ↗